U.S. markets open in 2 hours 58 minutes
  • S&P Futures

    3,890.75
    +23.25 (+0.60%)
     
  • Dow Futures

    31,570.00
    +212.00 (+0.68%)
     
  • Nasdaq Futures

    13,147.00
    +91.75 (+0.70%)
     
  • Russell 2000 Futures

    2,255.80
    +26.70 (+1.20%)
     
  • Crude Oil

    60.93
    +1.18 (+1.97%)
     
  • Gold

    1,722.90
    -10.70 (-0.62%)
     
  • Silver

    26.66
    -0.22 (-0.81%)
     
  • EUR/USD

    1.2082
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.4150
    0.0000 (0.00%)
     
  • Vix

    23.02
    -0.33 (-1.41%)
     
  • GBP/USD

    1.3968
    +0.0012 (+0.08%)
     
  • USD/JPY

    106.9700
    +0.2600 (+0.24%)
     
  • BTC-USD

    51,662.82
    +2,621.77 (+5.35%)
     
  • CMC Crypto 200

    1,032.18
    +44.09 (+4.46%)
     
  • FTSE 100

    6,672.77
    +59.02 (+0.89%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors focused on the Medical space have likely heard of Kala Pharmaceuticals (KALA), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Kala Pharmaceuticals is one of 892 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. KALA is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for KALA's full-year earnings has moved 12.38% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the latest available data, KALA has gained about 169.92% so far this year. Meanwhile, the Medical sector has returned an average of -3.48% on a year-to-date basis. This means that Kala Pharmaceuticals is outperforming the sector as a whole this year.

Looking more specifically, KALA belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual stocks and currently sits at #13 in the Zacks Industry Rank. Stocks in this group have gained about 2.08% so far this year, so KALA is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track KALA. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Kala Pharmaceuticals, Inc. (KALA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.